BRAF and colorectal cancer: In colorectal cancer, the BRAF V600E mutation is associated with a distinct clinical and pathological phenotype: predominantly proximal colon tumour location, aggressive growth, adverse metastasizing patterns, resistance to the EGFR blockade, and an overall survival (OS) rate that is 1.5 to 3 times shorter as compared to the general population.